Woman holding a box of VIZZ eyedrops

Make it VIZZable

with VIZZ, a once-daily prescription eye drop that gives you the power to restore near vision for up to 10 hours¹

The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.

99%

of patients achieved the ideal pupil size (<2mm) to restore near vision²

VIZZ is an aceclidine-based eye drop that selectively targets the pupil¹

Aceclidine, the active ingredient in VIZZ¹:

Is a pupil-selective miotic

Avoids overstimulating the ciliary muscle

Instillation site irritation was reported in 20% of study participants. The majority of adverse reactions were mild, transient, and self-resolving.

Person looking at laptop

VIZZ lasts up to 10 hours with a once-daily dose1

  • 91%

    of patients improved their near vision by at least 2 lines within 30 minutes2

  • 69%

    of patients improved their near vision by at least 2 lines at 10 hours2

% of Participants Achieving ≥2- and ≥3-Line Near Vision Improvement1,2

Day 1, CLARITY 2, full analysis set (VIZZ: n=77; vehicle: n=76). 3-line vehicle 5%-12%, 2-line vehicle 17%-24%. CLARITY 2 trial: Near visual acuity was assessed at 40cm using monocular DCNVA (distance-corrected near visual acuity). CLARITY was a Phase 3, multicenter, double-masked, randomized, controlled efficacy and safety study of VIZZ (1.44% aceclidine) for the treatment of presbyopia. The primary efficacy endpoint was the percentage of patients who achieved ≥3 lines of improvement in DCNVA without losing 1 line (5 letters) or more of distance vision at 3 hours post treatment on Day 1. VIZZ achieved all primary and secondary endpoints (in all cases, P<0.0001).¹,²

Patients may experience dim or dark vision. Dim vision was reported in 16% of study participants.

Functional near vision: 93% achieved 20/40 or better near vision at 30 minutes, 69% at 10 hours2

Day 1, Clarity 1 & 2, Analysis of Binocular Distance Corrected Near Vision with logMAR ≤ 0.3 (~20/40 or J3)

Patients may experience dim or dark vision. Dim vision was reported in 16% of study participants.

VIZZ achieves functional near vision for up to 10 hours

~7 out of 10

patients achieved 20/40 (J3) at 10 hours

~7 out of 10 patients achieved 20/40 (J3) at 10 hours

VIZZ is well tolerated¹

  • No serious treatment-related adverse events¹

  • Most adverse events were mild and temporary¹

The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.

Once-daily VIZZ is simple for patients to use¹:

  • Instill one drop in each eye, wait 2 minutes and instill a second drop in each eye once daily from the same single-dose vial.

  • If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

  • Contact lenses should be removed prior to instillation of VIZZ and may be reinserted 10 minutes following its administration.

  • No contraindications.

Who is VIZZ right for?

The majority of presbyopes would seriously consider a new presbyopia solution.² Who should you prioritize?

Headaches were reported in 13% of study participants. The majority of adverse reactions were mild, transient, and self-resolving.

VIZZ is easy to access.

Send VIZZ prescriptions to UpScript

Patients can save the most with UpScript

79/month

1-month supply (25 vials)

198($66/month)

Save more with a 3-month supply (75 vials)

Cash pay with no prior authorization required

padshadowpen

Eye redness: conjunctival hyperemia (8%) and ocular hyperemia (7%) was reported by participants in the study.

VIZZ is the first and only aceclidine-based eye drop for presbyopia1,4

Powered by aceclidine¹

Achieves ideal <2mm pupil size for clear near vision2

Lasts up to 10 hours with once-daily dosing¹

Well tolerated, with no serious treatment-related adverse events¹

Easy to access through UpScript or local pharmacies.

Sequelae of ocular inflammation, i.e., adhesions (synechiae) between the iris and the lens, may be exacerbated with miotic use in patients with a known history of iritis.

Resources

Designed to support you, your staff, and your patients once VIZZ is prescribed

Video

In Office VIZZ Video (MP4)
0:32

In Office VIZZ Video (MP4)

Download

Downloads

Patient Email Template: VIZZ is Now Available

Patient Email Template (PDF)

Download

Patient Email Template: Now Prescribing VIZZ

Patient Email Template (PDF)

Download

Patient Email Template: The Wait is Over

Patient Email Template (PDF)

Download

Patient Email Template: We Now Offer VIZZ

Patient Email Template (PDF)

Download

VIZZ Order Tear Pad

PDF Download

Download

Monitor Cling: VIZZ Prescribing Instructions

PDF Download

Download
Download
Indication

VIZZ is indicated for the treatment of presbyopia in adults.
Actor Portrayal

Important Safety Information

WARNINGS & PRECAUTIONS
Patients may experience temporary dim or dark vision.

Indication

VIZZ (aceclidine ophthalmic solution) 1.44% is indicated for the treatment of presbyopia in adults.

Important safety information

WARNINGS AND PRECAUTIONS

Patients may experience temporary dim or dark vision and should not drive or operate machinery if vision is not clear (e.g., blurred vision).

Rare cases of retinal tear and detachment have been reported with miotics when used in susceptible individuals and those with pre-existing retinal diseases.

Examination of the retina is advised in all patients prior to the initiation of treatment with VIZZ. Patients should be advised to seek immediate care with sudden onset of flashing lights, floaters, or vision loss.

Sequelae of ocular inflammation, i.e., adhesions (synechiae) between the iris and the lens, may be exacerbated with miotic use in patients with a known history of iritis.

VIZZ is not recommended for use in patients with a known hypersensitivity to aceclidine or any other ingredient in this product.

Contact lenses should be removed prior to the instillation of VIZZ, and may be reinserted 10 minutes after instillation.

To prevent eye injury or contamination, care should be taken to avoid touching the single-dose vial to the eye or to any other surface.

ADVERSE REACTIONS

The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.

To report SUSPECTED ADVERSE REACTIONS, contact LENZ Therapeutics, Inc. at 1- 888-711-LENZ or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional safety information, see full Prescribing Information.

© 2025 LENZ Therapeutics, Inc. All rights reserved. All trademarks are the property of their respective owners.
US-ACE-1316-v2 (v2.1) 10/25